Wednesday - May 22, 2019

Bayer launches Baycox® Iron Injection combination in Europe

The first patented toltrazuril plus gleptoferron injectable combination available in Europe helps protect suckling piglets from coccidiosis and iron deficiency with less handling and stress
more imagesdownload
Bayer’s Baycox® Iron Injection helps protect suckling piglets from coccidiosis and iron deficiency with less handling and stress.

Monheim, May 22, 2019 – Bayer launches Baycox® Iron (36 mg/ml toltrazuril plus 182 mg/ml gleptoferron) suspension for injection for piglets across Europe following marketing authorization from the European Commission.

Baycox® Iron Injection is indicated for the concurrent prevention of clinical signs of coccidiosis (such as diarrhoea) in neonatal piglets on farms with a confirmed history of coccidiosis caused by Cystoisospora suis, and the prevention of iron deficiency anaemia.

“Piglets go through intense handling in their first days of life. While this is done to give them a better start to life and protect them from disease, it can also cause a lot of stress. Measures to reduce the need for piglet handling can make an important contribution to enhancing piglet well-being in the farrowing pen,” said Professor Nicole Kemper, Director of the Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour, University of Veterinary Medicine Hannover, Germany.

Coccidiosis and iron deficiency in piglets are among every swine professionals’ key concerns.

“A combination therapy that can effectively address these concerns with reduced handling can make a real difference for pig health and well-being. At the same time, farmers and workers can benefit from the reduced labor. For example, on a 1,000 sow farm, the reduced complexity is estimated to save up to one full work day every month.(1) We are pleased to offer Baycox® Iron Injection to swine professionals across Europe, as an effective and convenient option to further improve swine health and management,” said Octavio Orlovsky Eckhardt, Head of Species Marketing Swine at Animal Health, Bayer.

For more information on Baycox® Iron Injection, contact your local Bayer Animal Health representative.

About Coccidiosis
Coccidiosis is a major parasitic disease affecting a wide range of domestic and wild animals. In pigs, Cystoisospora suis is the most pathogenic species of swine coccidian, mainly affecting suckling piglets and causing symptoms such as pasty to watery diarrhea and weight loss. The disease will impact a piglet’s health and performance throughout its life. Long-term consequences include lower growth rates, increasing the number of days to achieve market weight and related costs. Due to its worldwide presence, coccidiosis is considered to be one of major causes of economic losses for farmers.

About Iron Deficiency Anemia
Piglets are at risk of developing iron deficiency anemia in the early stages of their life due to their rapid growth, the limited iron reserves at birth, and the low levels of iron provided through the sow’s milk. Iron deficiency anemia will manifest in poor growth levels and ill thrift. To ensure proper health and development, supplementation of iron in the first week of the piglet’s life is a standard practice in swine farms worldwide.

About Baycox® Iron Injection
Bayer introduced the first toltrazuril based oral solution (Baycox® 5%) for swine more than 20 years ago, helping farmers to prevent the clinical signs of coccidiosis (such as diarrhoea) in neonatal piglets with a single oral treatment. The latest innovation, Baycox® Iron (36 mg/ml toltrazuril plus 182 mg/ml gleptoferron) suspension for injection for piglets, combines the prevention of clinical signs of coccidiosis with the prevention of iron deficiency anaemia in one easy-to-administer injection. It is available in Europe in a 100ml bottle.

(1) Calculation based on the assumption of 2.4 farrowings per sow per year, 14 piglets born alive per litter, 10 seconds for toltrazuril oral application.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to

Find more information at

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Download Center
file(s) collected

View Download Center